Respiratory Pharmacology: Antitussives and Expectorants

Introduction/Overview

Management of cough is a central component of respiratory care, as cough may be a presenting symptom in a multitude of pulmonary and systemic disorders. Cough can be classified physiologically into a protective reflex and a pathological manifestation, with the latter frequently necessitating pharmacologic intervention. Antitussives and expectorants represent two principal therapeutic classes that modulate cough reflex sensitivity and alter sputum properties, respectively. Their judicious use can alleviate patient discomfort, improve sleep quality, and reduce the risk of aspiration or respiratory complications. The pharmacologic landscape of these agents has evolved considerably over the past decades, with a growing emphasis on evidence-based selection, dosing optimization, and safety monitoring.

Learning objectives for this chapter include:

• Identify the major drug classes used as antitussives and expectorants and describe their chemical classifications.
• Explain the pharmacodynamic mechanisms and receptor interactions underlying cough suppression and mucus clearance.
• Outline the pharmacokinetic profiles that influence dosing regimens and therapeutic monitoring.
• Recognize approved indications, off‑label uses, and clinical scenarios where these agents are most effective.
• Appreciate the spectrum of adverse effects, drug interactions, and special population considerations relevant to antitussive and expectorant therapy.

Classification

Antitussives

Antitussives are divided into two broad categories: central-acting agents, which dampen the cough center within the medulla, and peripheral agents, which inhibit afferent nerve activity or directly modulate airway receptors.

Central‑acting antitussives include opioid derivatives such as codeine and dextromethorphan, as well as non‑opioid agents like butorphanol and the centrally active alkaloid, chlorpheniramine (in certain formulations).

Peripheral antitussives encompass topical cough suppressants like menthol and camphor, and agents that modify airway irritability, such as the anticholinergic atropine in low oral doses. Additionally, certain antihistamines with antitussive properties are employed in specific contexts.

Expectorants

Expectorants are primarily characterized by their influence on mucus rheology. The most widely used expectorant is guaifenesin, an isomer of the 2‑hydroxyethyl-3‑fluoro‑4‑propyl‑benzene derivative. Other expectorants, though less common, include acetylcysteine (a mucolytic), bromhexine, and carbocysteine, which act by breaking disulfide bonds or enhancing mucociliary clearance.

Chemical Classification

Opioid‑derived antitussives are structurally related to the morphinan scaffold, whereas dextromethorphan is a levorotatory analog of the synthetic opioid, differing in stereochemistry and receptor affinity. Guaifenesin belongs to the aryl alcohol class, with a phenolic structure that facilitates interaction with mucus components. Mucolytic agents such as acetylcysteine are thiol-containing compounds that reduce disulfide cross‑linking within mucoproteins.

Mechanism of Action

Central‑acting Antitussives

Codeine exerts its antitussive effect primarily through conversion to morphine in hepatic tissues, which then binds to µ‑opioid receptors located in the cough center of the medulla oblongata. Binding induces hyperpolarization of neuronal membranes, decreasing neuronal excitability and attenuating the cough reflex threshold. Dextromethorphan, although structurally related to morphine, acts as a non‑competitive antagonist at N‑methyl‑D‑aspartate (NMDA) receptors, limiting excitatory neurotransmission within the cough pathway. Additionally, dextromethorphan demonstrates σ‑1 receptor agonism, which may contribute to its antitussive activity by modulating ion channel conductance and intracellular signaling cascades that influence respiratory reflexes.

Peripheral antitussives such as menthol and camphor are believed to activate transient receptor potential melastatin 8 (TRPM8) channels on airway sensory neurons, inducing a cooling sensation that transiently desensitizes the cough reflex. Anticholinergic agents reduce cholinergic neurotransmission within the airway mucosa, decreasing bronchial secretions and attenuating cough triggers.

Expectorants

Guaifenesin is thought to increase the volume and fluidity of bronchial secretions by augmenting the osmotic pressure within the mucus layer, thereby facilitating ease of expectoration. Its precise molecular target remains incompletely delineated; however, it is postulated that guaifenesin interacts with mucin glycoproteins, disrupting inter‑molecular hydrogen bonds and decreasing mucus viscosity. Acetylcysteine, bromhexine, and carbocysteine act as mucolytic agents by cleaving disulfide bonds in mucin glycoproteins through their sulfhydryl groups. This structural modification reduces mucus cross‑linking, decreases viscoelasticity, and enhances mucociliary transport. Additionally, some mucolytics possess anti‑inflammatory properties, contributing to improved airway function over time.

Pharmacokinetics

Central‑acting Antitussives

Codeine is absorbed rapidly from the gastrointestinal tract, achieving peak plasma concentrations within 30–60 minutes. Approximately 30–50% of systemic codeine undergoes hepatic biotransformation via CYP2D6 to morphine, with the remainder excreted unchanged. The half‑life of codeine ranges from 2 to 4 hours, while morphine exhibits a half‑life of 3 to 4 hours. Because codeine metabolism is highly polymorphic, inter‑individual variability in analgesic and antitussive response is substantial. Dextromethorphan displays extensive first‑pass metabolism mediated by CYP2D6 and CYP3A4, yielding active metabolites such as dextrorphan. Peak plasma concentrations are reached within 1–2 hours; the parent compound has a half‑life of approximately 3–4 hours, while metabolites may persist longer. CYP2D6 polymorphisms influence dextromethorphan clearance; poor metabolizers may experience increased central nervous system effects, whereas ultra‑rapid metabolizers may exhibit reduced efficacy.

Expectorants

Guaifenesin is absorbed via the small intestine with an oral bioavailability of approximately 50–60%. Peak plasma concentrations are achieved after 1–2 hours of dosing. The elimination half‑life is roughly 4 to 6 hours, with renal excretion accounting for the majority of clearance. Acetylcysteine is administered orally or intravenously, with oral bioavailability limited by first‑pass metabolism. Intravenous acetylcysteine is rapidly distributed, achieving peak plasma concentrations within minutes, and is eliminated primarily via glucuronidation and subsequent renal excretion. Mucolytic agents such as bromhexine and carbocysteine undergo hepatic metabolism, with biliary excretion constituting a significant elimination pathway. The pharmacokinetic profiles of these agents inform dosing intervals, typically ranging from 6 to 12 hours for guaifenesin and 4 to 6 hours for acetylcysteine.

Therapeutic Uses/Clinical Applications

Antitussives

Codeine and dextromethorphan are approved for symptomatic relief of cough associated with upper respiratory tract infections, bronchitis, and other conditions that elicit frequent coughing. Codeine is often reserved for moderate to severe cough due to its opioid nature and associated safety concerns. Dextromethorphan is frequently employed in over‑the‑counter preparations, providing a non‑opioid alternative for mild to moderate cough. Peripheral antitussives may be used adjunctively in chronic cough syndromes, such as cough variant asthma or post‑nasal drip, where mechanical irritation predominates. Anticholinergic agents may be considered in patients with chronic bronchitis exhibiting increased mucus production that contributes to cough.

Expectorants

Guaifenesin is indicated for the treatment of upper or lower respiratory tract infections characterized by productive cough and thick mucus. Its role is to facilitate sputum clearance and reduce cough frequency. Acetylcysteine is employed in conditions marked by excessive mucus viscosity, such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), and severe bronchiectasis. Bromhexine and carbocysteine are utilized in chronic airway disease to improve mucociliary clearance, reduce exacerbation frequency, and ameliorate dyspnea. Off‑label applications include the use of mucolytics in acute bronchial asthma to reduce airway obstruction, although evidence varies across studies.

Adverse Effects

Central‑acting Antitussives

Codeine may produce constipation, nausea, vomiting, dizziness, sedation, and respiratory depression, particularly at higher doses or in susceptible individuals. The risk of dependence and withdrawal is present, given its opioid derivation. Dextromethorphan is generally well tolerated; however, at supratherapeutic doses, it can induce dissociative, hallucinogenic, or psychomimetic effects. Other adverse events include dizziness, nausea, and, rarely, serotonin syndrome when combined with serotonergic agents. Peripheral antitussives such as menthol may cause skin irritation or mild allergic reactions. Anticholinergic agents can provoke dry mouth, blurred vision, urinary retention, and tachycardia.

Expectorants

Guaifenesin is typically associated with mild gastrointestinal upset, including nausea, diarrhea, or abdominal discomfort. Allergic reactions are uncommon but may manifest as rash or pruritus. Acetylcysteine, particularly when administered intravenously, can lead to anaphylactoid reactions, hypotension, or bronchospasm, necessitating pre‑medication in sensitive patients. Oral mucolytics such as bromhexine may cause dysgeusia or mild gastrointestinal upset. Carbocysteine is generally well tolerated, though rare cases of rash or hypersensitivity have been reported.

Black Box Warnings

Codeine carries a black box warning regarding the risk of respiratory depression, particularly in infants and young children following tonsillectomy or adenoidectomy. Dextromethorphan lacks a black box warning but requires caution in patients with serotonergic medication use.

Drug Interactions

Central‑acting Antitussives

Codeine’s analgesic and antitussive effects can be potentiated by other central depressants, including benzodiazepines, barbiturates, or alcohol, increasing the risk of respiratory depression. CYP2D6 inhibitors such as fluoxetine or paroxetine reduce codeine conversion to morphine, diminishing efficacy. Conversely, CYP2D6 inducers such as rifampin accelerate conversion, potentially increasing morphine plasma levels and toxicity.

Dextromethorphan shares metabolic pathways with CYP2D6 and CYP3A4. Inhibitors of these enzymes, including fluoxetine, fluvoxamine, or ketoconazole, can elevate dextromethorphan concentrations, raising the risk of serotonergic toxicity or central nervous system adverse effects. Concurrent use with serotonergic agents (SSRIs, SNRIs, MAOIs) may precipitate serotonin syndrome. Anticholinergic agents may potentiate antitussive effects but also increase anticholinergic burden, leading to dry mouth, constipation, or cognitive impairment.

Expectorants

Guaifenesin has minimal drug interactions; however, it can potentially reduce the absorption of certain oral medications due to increased gastric motility. Acetylcysteine may interfere with the absorption of some antibiotics or antiepileptic drugs. Bromhexine and carbocysteine can alter the metabolism of drugs processed by CYP3A4, albeit to a limited extent. Clinicians should monitor for additive mucolytic effects when combining multiple agents.

Special Considerations

Pregnancy and Lactation

Codeine is classified as Category C; it can cross the placenta and has been associated with neonatal respiratory depression and neonatal abstinence syndrome. Dextromethorphan is also Category C, though evidence suggests minimal risk at therapeutic doses. Guaifenesin is Category B and is generally considered safe during pregnancy. Acetylcysteine is Category B as well. Mucolytics such as bromhexine and carbocysteine lack robust data but are typically used cautiously. Lactation: Codeine is excreted in breast milk and can cause infant sedation or respiratory depression; therefore, it is contraindicated. Dextromethorphan is present in low concentrations; risk appears minimal, but caution is advised. Guaifenesin is excreted in breast milk; the risk is low, but monitoring is recommended. Acetylcysteine and other mucolytics have limited data; careful assessment of risk-benefit is warranted.

Pediatric Considerations

Infants and young children are particularly susceptible to the respiratory depressant effects of codeine and dextromethorphan; therefore, dosing must be strictly weight‑based, and alternative antitussives should be considered. Guaifenesin is approved for use in children over 6 years old, with age‑adjusted dosing. Acetylcysteine is employed in pediatric patients with cystic fibrosis or severe bronchitis, but dosing adjustments and monitoring for adverse effects are essential. Mucolytics such as bromhexine and carbocysteine have limited pediatric use; safety data are sparse, requiring cautious application.

Geriatric Considerations

Older adults may exhibit increased sensitivity to central nervous system side effects of opioids and dextromethorphan. Renal and hepatic function decline with age, potentially prolonging drug clearance and increasing exposure. Dose adjustments based on pharmacokinetic changes and comorbidities are advised. Guaifenesin and acetylcysteine are generally well tolerated, though the elderly may experience hypotension or bradycardia with acetylcysteine infusion. Polypharmacy increases the risk of drug interactions, necessitating thorough medication review.

Renal and Hepatic Impairment

In hepatic impairment, the metabolism of codeine to morphine and dextromethorphan to dextrorphan is reduced, potentially leading to accumulation and toxicity. Dose reduction or avoidance is recommended. Renal impairment can increase the exposure to guaifenesin and acetylcysteine; however, guaifenesin has a relatively wide therapeutic index, and dose adjustment is seldom required. Acetylcysteine dosing may need modification in severe renal dysfunction due to altered excretion. Mucolytics metabolized by the liver may require dose adjustments in hepatic disease.

Summary/Key Points

• Antitussives are bifurcated into central‑acting (opioid and non‑opioid) and peripheral agents, each targeting distinct components of the cough reflex.
• Expectorants primarily function by altering mucus viscosity or enhancing mucociliary clearance through mucolytic activity.
• Codeine’s antitussive effect is contingent upon CYP2D6-mediated conversion to morphine, a process subject to substantial inter‑individual variability.
• Dextromethorphan’s NMDA antagonism and σ‑1 receptor interactions constitute its principal mechanism, with caution warranted in patients on serotonergic therapies.
• Guaifenesin’s role as an expectorant is supported by clinical evidence for productive cough, while acetylcysteine remains a cornerstone in cystic fibrosis and COPD management.
• Adverse effect profiles vary: opioid antitussives risk respiratory depression and dependence; dextromethorphan may cause dissociation at high doses; mucolytics may provoke gastrointestinal upset or hypersensitivity.
• Drug interactions involving CYP2D6, CYP3A4, and serotonergic pathways necessitate vigilant medication reconciliation.
• Special populations—including pregnant women, infants, the elderly, and patients with organ impairment—require dose adjustments or alternative therapies to mitigate risk.
• Clinical decision-making should integrate patient-specific factors, pharmacokinetic considerations, and evidence-based guidelines to optimize cough management while minimizing adverse outcomes.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
3. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.